de Maat MPM - Search Results

1

Reductions in plasmin inhibitor and fibrinogen predict the improved fibrin clot lysis 6 months after obesity surgery.

Pedersen NB, Stolberg CR, Mundbjerg LH, Juhl CB, Gram B, Funch-Jensen P, de Maat MPM, Münster AB, Bladbjerg EM. Pedersen NB, et al. Among authors: de maat mpm. Clin Obes. 2020 Dec;10(6):e12397. doi: 10.1111/cob.12397. Epub 2020 Aug 22. Clin Obes. 2020. PMID: 32827201

2

DNA-polymorphisms and plasma levels of vascular disease risk factors in Greenland Inuit--is there a relation with the low risk of cardiovascular disease in the Inuit?

de Maat MP, Bladbjerg EM, Johansen LG, de Knijff P, Gram J, Kluft C, Jespersen J. de Maat MP, et al. Thromb Haemost. 1999 Apr;81(4):547-52. Thromb Haemost. 1999. PMID: 10235437

3

Longevity is independent of common variations in genes associated with cardiovascular risk.

Bladbjerg EM, Andersen-Ranberg K, de Maat MP, Kristensen SR, Jeune B, Gram J, Jespersen J. Bladbjerg EM, et al. Thromb Haemost. 1999 Sep;82(3):1100-5. Thromb Haemost. 1999. PMID: 10494771

4

Internal quality control of PCR-based genotyping methods in research studies and patient diagnostics.

Bladbjerg EM, Gram J, Jespersen J, de Maat MP. Bladbjerg EM, et al. Thromb Haemost. 2002 May;87(5):812-6. Thromb Haemost. 2002. PMID: 12038782

5

Internal quality control of PCR-based genotyping methods: practical experiences.

Bladbjerg EM, Gram J, Jespersen J, de Maat MP. Bladbjerg EM, et al. Vascul Pharmacol. 2002 Aug;39(3):127-9. doi: 10.1016/s1537-1891(02)00299-9. Vascul Pharmacol. 2002. PMID: 12616979

6

Biological variation in tPA-induced plasma clot lysis time.

Talens S, Malfliet JJ, Rudež G, Spronk HM, Janssen NA, Meijer P, Kluft C, de Maat MP, Rijken DC. Talens S, et al. Thromb Haemost. 2012 Oct;108(4):640-6. doi: 10.1160/TH12-02-0124. Epub 2012 Jul 26. Thromb Haemost. 2012. PMID: 22836204

7

Comprehensive characteristics of the anticoagulant activity of dabigatran in relation to its plasma concentration.

Comuth WJ, Henriksen LØ, van de Kerkhof D, Husted SE, Kristensen SD, de Maat MPM, Münster AB. Comuth WJ, et al. Among authors: de maat mpm. Thromb Res. 2018 Apr;164:32-39. doi: 10.1016/j.thromres.2018.02.141. Epub 2018 Feb 17. Thromb Res. 2018. PMID: 29475179

8

Adherence to dabigatran etexilate in atrial fibrillation patients intended to undergo electrical cardioversion.

Comuth WJ, de Maat MPM, van de Kerkhof D, Malczynski J, Husted S, Kristensen SD, Münster AB. Comuth WJ, et al. Among authors: de maat mpm. Eur Heart J Cardiovasc Pharmacother. 2019 Apr 1;5(2):91-99. doi: 10.1093/ehjcvp/pvy047. Eur Heart J Cardiovasc Pharmacother. 2019. PMID: 30608563 Clinical Trial.

9

Citrullination of fibrinogen by peptidylarginine deiminase 2 impairs fibrin clot structure.

Damiana T, Damgaard D, Sidelmann JJ, Nielsen CH, de Maat MPM, Münster AB, Palarasah Y. Damiana T, et al. Among authors: de maat mpm. Clin Chim Acta. 2020 Feb;501:6-11. doi: 10.1016/j.cca.2019.10.033. Epub 2019 Nov 12. Clin Chim Acta. 2020. PMID: 31730822

10

FIBTEM clot firmness parameters correlate well with the fibrinogen concentration measured by the Clauss assay in patients and healthy subjects.

de Vries JJ, Veen CSB, Snoek CJM, Kruip MJHA, de Maat MPM. de Vries JJ, et al. Among authors: de maat mpm. Scand J Clin Lab Invest. 2020 Nov;80(7):600-605. doi: 10.1080/00365513.2020.1818283. Epub 2020 Sep 14. Scand J Clin Lab Invest. 2020. PMID: 32924629

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

329 results

Search Page

Filters